Baudax Bio Inc. (BXRX) has received FDA approval for ANJESO, which is indicated for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics.
ANJESO that will be administered as a once-a-day intravenous (IV) bolus push is the only available 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) and offers once-daily dosing.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com